<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802866</url>
  </required_header>
  <id_info>
    <org_study_id>4429-202</org_study_id>
    <nct_id>NCT01802866</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride</brief_title>
  <acronym>SEATTLE</acronym>
  <official_title>A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acucela Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acucela Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the
      rate of progression of geographic atrophy compared to placebo in subjects with dry
      age-related macular degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the total area of the GA lesion(s)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BCVA score</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs, discontinuations due to AEs, or dose modifications; severity and seriousness of AEs</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>ACU-4429 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACU-4429 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACU-4429 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Includes identical tablets with only inactive ingredients (0 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACU-4429</intervention_name>
    <description>Take orally once daily for 24 months</description>
    <arm_group_label>ACU-4429 2.5 mg</arm_group_label>
    <arm_group_label>ACU-4429 5 mg</arm_group_label>
    <arm_group_label>ACU-4429 10 mg</arm_group_label>
    <other_name>emixustat hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take orally once daily for 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females, age â‰¥55 years.

          2. Clinical diagnosis of GA associated with AMD

          3. Able and willing to provide written informed consent.

          4. Able to reliably administer oral medication by self or with available assistance.

        Exclusion Criteria:

          1. Active CNV or presence of an active ocular disease.

          2. Known serious allergy to the fluorescein sodium for injection in angiography.

          3. Pre-specified laboratory abnormalities at screening.

          4. Treatment with any investigational study drug within 30 days of screening or device
             (within 60 days of screening)

          5. History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding

          6. Female subjects who are pregnant or lactating.

          7. Female subjects of childbearing potential and male subjects who are not surgically
             sterile who are not willing to practice a medically accepted method of birth control
             from screening through 30 days after completion of the study.

          8. Unstable or poorly controlled medical or ophthalmic conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Acucela Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Acucela Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2013</study_first_posted>
  <disposition_first_submitted>June 26, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>June 26, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 2, 2017</disposition_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Geographic atrophy</keyword>
  <keyword>GA</keyword>
  <keyword>Dry AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

